TrialThe Lancet. Oncology2010

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Steven E Lipshultz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.